Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAKT: Imatinib plus pembrolizumab in advanced KIT-mutant melanoma
jRCTs031190202Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib and pembrolizumab in melanoma, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate after four dosing cycles. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCTs031190202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190202.